Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.
Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. That said, here are two growth stocks where the best is yet to come and one whose momentum may slow.
One Growth Stock to Sell:
Upstart (UPST)
One-Year Revenue Growth: +73.3%
Using over 2,500 data variables and trained on nearly 82 million repayment events, Upstart (NASDAQ: UPST) is an AI-powered lending platform that uses machine learning to help banks and credit unions more accurately assess borrower risk for personal loans, auto loans, and home equity lines of credit.
Why Are We Wary of UPST?
- Extended payback periods on sales investments suggest the company’s platform isn’t resonating enough to drive efficient sales conversions
- Cash burn makes us question whether it can achieve sustainable long-term growth
- Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution
At $43.01 per share, Upstart trades at 4.1x forward price-to-sales. If you’re considering UPST for your portfolio, see our FREE research report to learn more.
Two Growth Stocks to Watch:
FuelCell Energy (FCEL)
One-Year Revenue Growth: +41%
Founded in 1969, FuelCell Energy (NASDAQ: FCEL) is a leading manufacturer and developer of carbonate fuel cell technology for stationary power generation.
Why Is FCEL a Top Pick?
- Average backlog growth of 9.9% over the past two years shows it has a steady sales pipeline that will drive future orders
- Earnings per share grew by 25.9% annually over the last two years, massively outpacing its peers
- Cash burn has decreased over the last five years, showing the company is becoming a more self-sustaining business
FuelCell Energy is trading at $9.47 per share, or 1.8x forward price-to-sales. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.
Cigna (CI)
One-Year Revenue Growth: +15.2%
With roots dating back to 1792 and serving millions of customers across the globe, The Cigna Group (NYSE: CI) provides healthcare services through its Evernorth Health Services and Cigna Healthcare segments, offering pharmacy benefits, specialty care, and medical plans.
Why Are We Positive On CI?
- Market share has increased this cycle as its 18.8% annual revenue growth over the last two years was exceptional
- Massive revenue base of $267.8 billion gives it meaningful leverage when negotiating reimbursement rates
- Earnings per share grew by 8.1% annually over the last five years, above the peer group average
Cigna’s stock price of $271.85 implies a valuation ratio of 8.8x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Stocks We Like Even More
If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.
Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
